更紧凑的生命科学资讯库。
先搜索,再按来源或主题继续收窄。
罗氏:乳腺癌候选药物Giredestrant数据支持其潜在差异化地位——晨星加拿大
Roche: Data for Breast Cancer Drug Candidate Giredestrant Support Potential Differentiated Status Morningstar Canada
罗氏癌症药物试验结果积极,OLMA股价翻倍——Stocktwits报道
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results Stocktwits
新型实验性药物或将改变癌症患者护理方式——独立报
New experimental drug could transform care for cancer patients The Independent
罗氏制药管线进展与股价飙升17%后,是否该重新评估其投资时机? - simplywall.st
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? simplywall.st
罗氏口服药物证实可抑制乳腺癌复发,提振股价——路透社
Roche oral drug shown to keep breast cancer at bay, boosting shares Reuters
罗氏推出新药,或将颠覆整个多发性硬化症市场——雅虎财经报道
Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market Khac Phu Nguyen November 10, 2025 1 min read ROG.SW +1.38% This article first appeared on GuruFocus....
罗氏实验性多发性硬化药物在两项关键试验中一项达到主要目标——路透社
Roche's experimental MS drug hits main goal in one of two key trials Reuters
罗氏携手AI专家研发新型脑部药物——BioPharma Dive报道
Roche taps an AI specialist to craft new brain drugs BioPharma Dive
罗氏CEO称正就药品定价与美国政府持续磋商——医药科技
Roche in ongoing discussions with US government over drug pricing, CEO says Pharmaceutical Technology
罗氏股价因新药销售不佳而下跌——路透社
Roche shares fall as new drug sales disappoint Reuters
罗氏实验性减肥药进入后期试验阶段,目标跻身行业前三强——CNBC报道
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial CNBC
罗氏进军减肥药竞赛,将肥胖治疗推进至后期试验阶段——路透社
Roche, muscling into weight-loss drug race, advances obesity treatment to late-stage trial Reuters
罗氏制药拟以高达35亿美元收购肝脏药物开发商89bio——路透社报道
Roche to acquire liver drug developer 89bio for up to $3.5 billion Reuters
罗氏在北卡罗来纳州启动建设价值7亿美元的肥胖症药物生产设施 - 激烈药业
Roche begins building $700M obesity drug manufacturing facility in N.C. Fierce Pharma
罗氏CEO称正考虑直接向美国患者销售药品——路透社
Roche considering selling drugs directly to US patients, CEO says Reuters
把品牌目录放在视野里,但不抢主叙事
把工具、CRO、生物制药和器械公司做成滚动资源带,作为资讯流下方的辅助索引。
查看关于页